Around 12,000 people each year in the United Kingdom develop gastric adenocarcinoma (Office of Population Censuses & Surveys, 1986) . For the majority of patients, the diagnosis means a strong likelihood of death. The 5 year survival is only 7-10% and in the UK there has been relatively little improvement in this outlook over the past 30 years . In Japan, earlier diagnosis, possibly linked to more aggressive surgery, has improved the situation so that up to 40% of patients are surgically cured (Maruyama, 1986) . Moreover, preliminary data suggest that we too may be making the diagnosis earlier now -but this has yet to be translated into improved survival outlook (Allum et al., 1986; Houghton et al., 1986) . In terms of surgical treatment in the UK and USA, 50-60% of patients have the primary tumour resected and approximately half of these patients will have been considered by the surgeon and histopathologist to have had a curative resection (Swynnerton & Truelove, 1952; Cassell & Robinson, 1976; Gilbertson, 1969; Dupont et al., 1978) . Despite this up to two thirds of patients in this curative resection group will relapse and die due to loco-regional failure (87%) and/or distant metastases (30%) (Gunderson & Sosin, 1982) . For the 40% of patients who cannot have a resection the outlook is particularly bad with a median survival of only 4 months reported in one recent series .
Given this background, it is hardly surprising that other treatment modalities have been investigated. Single agent chemotherapy such as 5-fluorouracil (5-FU), doxorubicin, carmustine and mitomycin-C produce objective tumour regression in approximately 15-25% of patients (Cunningham & Coombes, 1986) . However, complete remissions are rare and partial remissions are of short duration, usually 4-5 months. The most recent additions to the list of active single agents are the folate antagonist triazinate , epirubicin the doxorubicin analogue (Cerasimo & Hong, 1986) and cisplatin . Cisplatin is particularly interesting since an overall response rate of 25% was reported in studies which included heavily pre-treated patients .
The Mayo Clinic were among the first to investigate combination chemotherapy. In one study patients were randomly allocated to 5-FU and methyl-CCNU or methyl-CCNU alone. Response to the combination was 40% and the patients survived significantly longer following treatment with 5-FU but a subsequent study failed to confirm these results (Moertel et al., 1976; Baker et al., 1976) . Adriamycin has been added to the combination of 5-FU and methyl-CCNU (The Gastrointestinal Tumour Study Group (GITSG), 1979; . When the results of these studies are comibined the response rate is only 35% (14 out of 40 patients with measurable disease). Levi et al. treated 35 evaluable patients with the combination of 5-FU adriamycin and BCNU (FAB) and found 18 (51%) patients responded with a median duration of response of 10 months. However, a subsequent randomised study from this group showed no difference in the survival of patients treated with single agent adriamycin compared with FAB (Levi et al., 1986) . Until recently, the most widely used regimen in gastric cancer was the combination of 5-FU, adriamycin and mitomycin-C (FAM) (MacDonald et al., 1979) . Preliminary results suggested that over 50% patients would respond to the combination but subsequent data has shown the figure to be nearer 40% (Table I ). Response to FAM usually occurs within the first cycle of chemotherapy and the median duration of response is 10-11 months (Cunningham et al., 1984; MacDonald et al., 1980) which is considerably better than can be achieved with any single agent treatment. In general, it has proven extremely difficult to predict patients most likely to respond to FAM. The GITSG have shown good performance status, extra-abdominal lymphadenopathy and pulmonary metastases to be associated with a positive response to chemot,herapy but this is yet to be confirmed by another group (Lavin et al., 1982 ). An interesting development in our FAM study was that 4 of 16 patients with inoperable tumours who responded to FAM were subsequently able to have the primary tumour resected. These findings highlight the potential benefits of integrating chemotherapy and surgery in the management of gastric cancer. However, with regard to FAM a recent randomised study from the North Central Cancer Treatment Group in which 151 patients were allocated to single agent 5-CU, 5-FU and adriamycin or FAM, failed to show a survival advantage for any treatment arm (Cullinan et al., 1985) . Using the combination of triazinate and mitomycin-C, O'Connell et al. treated 33 patients with advanced gastric cancer, 29 of whom had failed previous chemotherapy. Nine (27%) patients had a partial response. This finding is especially germane because of the high proportion of pre-treated patients who went on to respond to second line therapy. Bertino and his colleagues were the first to demonstrate a synergism between 5-FU and methotrexate (Bertino et al., 1977) . They showed enhanced cytotoxic activity in a variety of tumour models when methotrexate was given sequentially to 5-FU. Klein utilised this effect in the treatment of gastric cancer and reported a very high response to the combination of 5-FU, methotrexate and adriamycin (FAMTX) (Klein et al., 1983) . The Klein data and the results from 2 other studies (Cunningham et al., 1985; Wils et al., 1986) are shown in Table II . This combination appears to have considerable activity in gastric cancer but the main reservation is its toxicity. In our hands it was associated with unpredictable myelosuppression and in the EORTC study (Wils et al., 1986) , its use was associated with 4 toxic deaths although 3 of these occurred in patients where the treatment protocol had been violated. The EORTC have recently completed a randomised trial of FAM versus FAMTX and the results are awaited with interest.
Cisplatin has shown promising activity as a single agent and it has been incorporated now into a number of combination chemotherapy regimens (Table III) . Wagener et al. treated 20 patients with 5-FU, adriamycin and cisplatin. Nine (50%) of the 18 evaluable patients entered partial remission and 8 patients had stable disease. Similarly the combination of cisplatin, adriamycin and etoposide produced objective tumour regression in 10 (62.5%) of 16 patients (Preusser et al., 1986) . Recent data has also shown significant activity for cisplatin in combination with 5-FU (Lacave et al., 1987) or with etoposide and doxorubicin (EAP) (Preusser et al., 1987) . Furthermore at this year's meeting of the American Society of Clinical Oncology (ASCO) the same group reported on the use of EAP as neo-adjuvant chemotherapy in locally advanced gastric cancer. Twenty-seven patients were treated with 2-4 cycles pre-operatively followed where appropriate by 2 cycles of EAP post-operatively. Six patients had a complete response to treatment and 13 had a partial response giving an overall response rate of 70%. Of the 15 patients who went on to surgery, 5 were complete pathological remissions. So far, the relapse rate is 20% and the median survival for the group is 20.5 months (Preusser et al., 1988) . Unfortunately success with cisplatin containing regimens has not been universal. A study from the USA (Cazap et al., 1986 ) which investigated 5-FU, adriamycin and cisplatin revealed that only 10 (29%) of 35 patients responded and a further study in which cisplatin was combined with etoposide showed only 1 of 33 patients responded (Kelsen et al., 1987) . However, overall the evidence now favours the use of cisplatin-based regimens.
There have been several trials of adjuvant chemotherapy in gastric cancer (Longmire et al., 1968; Dixon et al., 1971; Serlin et al., 1969; Douglas & Stanlein, 1982; Engestrom et al., 1985; Higgins et al., 1983; Boice et al., 1983; Fielding et al., 1983 ) and all of these, apart from one (Douglas & Stanlein, 1982) , have failed to show any benefit on survival. Indeed, two further randomised trials presented at this year's ASCO, one comparing the combination of doxorubicin and 5-fluorouracil with no treatment (Krook et al., 1988) , and one comparing FAM with no treatment (Wils et al., 1988) , showed no benefit from adjuvant chemotherapy. It could be argued that some of the early studies were premature since they evaluated treatments in an adjuvant setting which had relatively little activity in advanced disease. We have recently shown that the major determinant of survival in patients having a curative resection for gastric cancer is the depth of penetration of the tumour; patients whose tumour penetrates the serosa have a 5 year survival of 13% compared to a 47% for those without serosal penetration . One of the reasons for the high recurrence rate in the patients with serosal penetration is that 20-30% will have malignant cells in peritoneal washings taken at the time of surgery (Nakajima et al., 1978) . Therefore, it may be possible to improve their outlook by the administration of (Fanning et al., 1988) . In man the investigation of intraperitoneal biological response modifiers has so far been limited but it would seem appropriate to test them in this context. Gastric cancer is now recognised as being relatively sensitive to treatment with cytotoxic drugs. In advanced disease complete remissions are possible particularly with cisplatin-based regimens. With the advent of more effective anti-emetics it is now possible to deliver cisplatin with less acute gastrointestinal toxicity, thus these regimens should make a contribution to quality as well as quantity of life. Much work still needs to be done and a clearer understanding of the mechanism of action of cytotoxic drugs, such a topoisomerase II inhibition should permit the evolution of better chemotherapy regimens. Integration of cytotoxic drug therapy into other treatment modalities will be important. There is, however a caveat; at the present time there is no 'standard' chemotherapy regimen for gastric cancer. Where possible patients should be treated in the context of clinical trials so that an improved understanding of the biology of this disease and its treatment may allow us to re-draw the survival curves in the future. 
